Global Dermatology Drugs Market

Dermatology Drugs Comprehensive Study by Type (Prescription-Based Drugs, Over-the-Counter Drugs), Application (Psoriasis, Skin Infections, Acne, Dermatitis, Other), Forms (Tablets, External Use, Injection) Players and Region - Global Market Outlook to 2028

Dermatology Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Dermatology Drugs
Dermatology drugs are used to treat numerous skin conditions, these drug are applied directly on the skin or can be taken through injection. They may deliver medicines to prevent or treat skin disorders or have inert creams and gels for routine skin care to maintain the skin, which may be liable to skin disorders. A large number of drugs have been approved by the FDA and other regulatory bodies of different countries for some skin conditions and disorders. The dermatological indications such as pigmentation, acne, wrinkles, psoriasis and many other can be treated by the dermatology drugs.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


Dermatology Drugs is a fragmented market due to the presence of several regional and international players. The players are focusing on planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Dermatology Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bayer AG (Germany), Johnson & Johnson (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), GlaxoSmithKline plc (United Kingdom), AstraZeneca (United Kingdom), Galderma S.A (Switzerland), Amgen Inc. (United States), AbbVie Inc. (United States) and Merck KGaA. (Germany) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Dermatology Drugs market by Type (Prescription-Based Drugs and Over-the-Counter Drugs), Application (Psoriasis, Skin Infections, Acne, Dermatitis and Other) and Region.



On the basis of geography, the market of Dermatology Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Forms, the sub-segment i.e. Tablets will boost the Dermatology Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
High Demand for Quick Diagnosis and Rising Expenditure on Personal Care

Market Growth Drivers:
Increasing Skin Related Infection and Growing Demand for Topical Dermatological Drugs

Challenges:
Side Effect Related to Dermatology Drugs

Restraints:
Strict Government Regulations

Opportunities:
Development of Innovative Products

Market Leaders and their expansionary development strategies
In March 2023, March 2023, Bayer AG plans to spend USD1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer's top U.S. pharmaceutical executive.
In November 2023, Consumer Health division of Bayer have launched a strategic partnership to advance consumer innovations in the emerging area of healthy aging. The partnership is designed to enhance the companies’ shared ambition to transform self-care through personalized solutions.
Jeuveau which is an acetylcholine release inhibitor and a neuromuscular blocking agent has been approved by FDA in February 2019. Jeuveau is specifically indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Key Target Audience
Manufacturers of Dermatology Drug, Suppliers of Dermatology Drug, Wholesalers, Distributors and Retailers of Dermatology Drug, Healthcare Industry, Research Organization and Governmental Bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Prescription-Based Drugs
  • Over-the-Counter Drugs
By Application
  • Psoriasis
  • Skin Infections
  • Acne
  • Dermatitis
  • Other
By Forms
  • Tablets
  • External Use
  • Injection

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Skin Related Infection
      • 3.2.2. Growing Demand for Topical Dermatological Drugs
    • 3.3. Market Challenges
      • 3.3.1. Side Effect Related to Dermatology Drugs
    • 3.4. Market Trends
      • 3.4.1. High Demand for Quick Diagnosis
      • 3.4.2. Rising Expenditure on Personal Care
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dermatology Drugs, by Type, Application, Forms and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Dermatology Drugs (Value)
      • 5.2.1. Global Dermatology Drugs by: Type (Value)
        • 5.2.1.1. Prescription-Based Drugs
        • 5.2.1.2. Over-the-Counter Drugs
      • 5.2.2. Global Dermatology Drugs by: Application (Value)
        • 5.2.2.1. Psoriasis
        • 5.2.2.2. Skin Infections
        • 5.2.2.3. Acne
        • 5.2.2.4. Dermatitis
        • 5.2.2.5. Other
      • 5.2.3. Global Dermatology Drugs by: Forms (Value)
        • 5.2.3.1. Tablets
        • 5.2.3.2. External Use
        • 5.2.3.3. Injection
      • 5.2.4. Global Dermatology Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Dermatology Drugs (Volume)
      • 5.3.1. Global Dermatology Drugs by: Type (Volume)
        • 5.3.1.1. Prescription-Based Drugs
        • 5.3.1.2. Over-the-Counter Drugs
      • 5.3.2. Global Dermatology Drugs by: Application (Volume)
        • 5.3.2.1. Psoriasis
        • 5.3.2.2. Skin Infections
        • 5.3.2.3. Acne
        • 5.3.2.4. Dermatitis
        • 5.3.2.5. Other
      • 5.3.3. Global Dermatology Drugs by: Forms (Volume)
        • 5.3.3.1. Tablets
        • 5.3.3.2. External Use
        • 5.3.3.3. Injection
      • 5.3.4. Global Dermatology Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Dermatology Drugs (Price)
      • 5.4.1. Global Dermatology Drugs by: Type (Price)
  • 6. Dermatology Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Galderma S.A (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Amgen Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AbbVie Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck KGaA. (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Dermatology Drugs Sale, by Type, Application, Forms and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Dermatology Drugs (Value)
      • 7.2.1. Global Dermatology Drugs by: Type (Value)
        • 7.2.1.1. Prescription-Based Drugs
        • 7.2.1.2. Over-the-Counter Drugs
      • 7.2.2. Global Dermatology Drugs by: Application (Value)
        • 7.2.2.1. Psoriasis
        • 7.2.2.2. Skin Infections
        • 7.2.2.3. Acne
        • 7.2.2.4. Dermatitis
        • 7.2.2.5. Other
      • 7.2.3. Global Dermatology Drugs by: Forms (Value)
        • 7.2.3.1. Tablets
        • 7.2.3.2. External Use
        • 7.2.3.3. Injection
      • 7.2.4. Global Dermatology Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Dermatology Drugs (Volume)
      • 7.3.1. Global Dermatology Drugs by: Type (Volume)
        • 7.3.1.1. Prescription-Based Drugs
        • 7.3.1.2. Over-the-Counter Drugs
      • 7.3.2. Global Dermatology Drugs by: Application (Volume)
        • 7.3.2.1. Psoriasis
        • 7.3.2.2. Skin Infections
        • 7.3.2.3. Acne
        • 7.3.2.4. Dermatitis
        • 7.3.2.5. Other
      • 7.3.3. Global Dermatology Drugs by: Forms (Volume)
        • 7.3.3.1. Tablets
        • 7.3.3.2. External Use
        • 7.3.3.3. Injection
      • 7.3.4. Global Dermatology Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Dermatology Drugs (Price)
      • 7.4.1. Global Dermatology Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dermatology Drugs: by Type(USD Million)
  • Table 2. Dermatology Drugs Prescription-Based Drugs , by Region USD Million (2017-2022)
  • Table 3. Dermatology Drugs Over-the-Counter Drugs , by Region USD Million (2017-2022)
  • Table 4. Dermatology Drugs: by Application(USD Million)
  • Table 5. Dermatology Drugs Psoriasis , by Region USD Million (2017-2022)
  • Table 6. Dermatology Drugs Skin Infections , by Region USD Million (2017-2022)
  • Table 7. Dermatology Drugs Acne , by Region USD Million (2017-2022)
  • Table 8. Dermatology Drugs Dermatitis , by Region USD Million (2017-2022)
  • Table 9. Dermatology Drugs Other , by Region USD Million (2017-2022)
  • Table 10. Dermatology Drugs: by Forms(USD Million)
  • Table 11. Dermatology Drugs Tablets , by Region USD Million (2017-2022)
  • Table 12. Dermatology Drugs External Use , by Region USD Million (2017-2022)
  • Table 13. Dermatology Drugs Injection , by Region USD Million (2017-2022)
  • Table 14. South America Dermatology Drugs, by Country USD Million (2017-2022)
  • Table 15. South America Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 16. South America Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 17. South America Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 18. Brazil Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 19. Brazil Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 20. Brazil Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 21. Argentina Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 22. Argentina Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 23. Argentina Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 24. Rest of South America Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 25. Rest of South America Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 26. Rest of South America Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 27. Asia Pacific Dermatology Drugs, by Country USD Million (2017-2022)
  • Table 28. Asia Pacific Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 29. Asia Pacific Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 30. Asia Pacific Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 31. China Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 32. China Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 33. China Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 34. Japan Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 35. Japan Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 36. Japan Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 37. India Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 38. India Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 39. India Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 40. South Korea Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 41. South Korea Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 42. South Korea Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 43. Taiwan Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 44. Taiwan Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 45. Taiwan Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 46. Australia Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 47. Australia Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 48. Australia Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 49. Rest of Asia-Pacific Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 52. Europe Dermatology Drugs, by Country USD Million (2017-2022)
  • Table 53. Europe Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 54. Europe Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 55. Europe Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 56. Germany Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 57. Germany Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 58. Germany Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 59. France Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 60. France Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 61. France Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 62. Italy Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 63. Italy Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 64. Italy Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 65. United Kingdom Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 66. United Kingdom Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 67. United Kingdom Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 68. Netherlands Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 69. Netherlands Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 70. Netherlands Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 71. Rest of Europe Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 72. Rest of Europe Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 73. Rest of Europe Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 74. MEA Dermatology Drugs, by Country USD Million (2017-2022)
  • Table 75. MEA Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 76. MEA Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 77. MEA Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 78. Middle East Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 79. Middle East Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 80. Middle East Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 81. Africa Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 82. Africa Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 83. Africa Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 84. North America Dermatology Drugs, by Country USD Million (2017-2022)
  • Table 85. North America Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 86. North America Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 87. North America Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 88. United States Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 89. United States Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 90. United States Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 91. Canada Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 92. Canada Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 93. Canada Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 94. Mexico Dermatology Drugs, by Type USD Million (2017-2022)
  • Table 95. Mexico Dermatology Drugs, by Application USD Million (2017-2022)
  • Table 96. Mexico Dermatology Drugs, by Forms USD Million (2017-2022)
  • Table 97. Dermatology Drugs Sales: by Type(K Units)
  • Table 98. Dermatology Drugs Sales Prescription-Based Drugs , by Region K Units (2017-2022)
  • Table 99. Dermatology Drugs Sales Over-the-Counter Drugs , by Region K Units (2017-2022)
  • Table 100. Dermatology Drugs Sales: by Application(K Units)
  • Table 101. Dermatology Drugs Sales Psoriasis , by Region K Units (2017-2022)
  • Table 102. Dermatology Drugs Sales Skin Infections , by Region K Units (2017-2022)
  • Table 103. Dermatology Drugs Sales Acne , by Region K Units (2017-2022)
  • Table 104. Dermatology Drugs Sales Dermatitis , by Region K Units (2017-2022)
  • Table 105. Dermatology Drugs Sales Other , by Region K Units (2017-2022)
  • Table 106. Dermatology Drugs Sales: by Forms(K Units)
  • Table 107. Dermatology Drugs Sales Tablets , by Region K Units (2017-2022)
  • Table 108. Dermatology Drugs Sales External Use , by Region K Units (2017-2022)
  • Table 109. Dermatology Drugs Sales Injection , by Region K Units (2017-2022)
  • Table 110. South America Dermatology Drugs Sales, by Country K Units (2017-2022)
  • Table 111. South America Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 112. South America Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 113. South America Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 114. Brazil Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 115. Brazil Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 116. Brazil Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 117. Argentina Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 118. Argentina Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 119. Argentina Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 120. Rest of South America Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 121. Rest of South America Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 122. Rest of South America Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 123. Asia Pacific Dermatology Drugs Sales, by Country K Units (2017-2022)
  • Table 124. Asia Pacific Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 125. Asia Pacific Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 126. Asia Pacific Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 127. China Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 128. China Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 129. China Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 130. Japan Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 131. Japan Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 132. Japan Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 133. India Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 134. India Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 135. India Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 136. South Korea Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 137. South Korea Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 138. South Korea Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 139. Taiwan Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 140. Taiwan Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 141. Taiwan Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 142. Australia Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 143. Australia Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 144. Australia Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 145. Rest of Asia-Pacific Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 146. Rest of Asia-Pacific Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 147. Rest of Asia-Pacific Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 148. Europe Dermatology Drugs Sales, by Country K Units (2017-2022)
  • Table 149. Europe Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 150. Europe Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 151. Europe Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 152. Germany Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 153. Germany Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 154. Germany Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 155. France Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 156. France Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 157. France Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 158. Italy Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 159. Italy Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 160. Italy Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 161. United Kingdom Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 162. United Kingdom Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 163. United Kingdom Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 164. Netherlands Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 165. Netherlands Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 166. Netherlands Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 167. Rest of Europe Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 168. Rest of Europe Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 169. Rest of Europe Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 170. MEA Dermatology Drugs Sales, by Country K Units (2017-2022)
  • Table 171. MEA Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 172. MEA Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 173. MEA Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 174. Middle East Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 175. Middle East Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 176. Middle East Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 177. Africa Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 178. Africa Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 179. Africa Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 180. North America Dermatology Drugs Sales, by Country K Units (2017-2022)
  • Table 181. North America Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 182. North America Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 183. North America Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 184. United States Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 185. United States Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 186. United States Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 187. Canada Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 188. Canada Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 189. Canada Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 190. Mexico Dermatology Drugs Sales, by Type K Units (2017-2022)
  • Table 191. Mexico Dermatology Drugs Sales, by Application K Units (2017-2022)
  • Table 192. Mexico Dermatology Drugs Sales, by Forms K Units (2017-2022)
  • Table 193. Dermatology Drugs: by Type(USD/Units)
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Dermatology Drugs: by Type(USD Million)
  • Table 205. Dermatology Drugs Prescription-Based Drugs , by Region USD Million (2023-2028)
  • Table 206. Dermatology Drugs Over-the-Counter Drugs , by Region USD Million (2023-2028)
  • Table 207. Dermatology Drugs: by Application(USD Million)
  • Table 208. Dermatology Drugs Psoriasis , by Region USD Million (2023-2028)
  • Table 209. Dermatology Drugs Skin Infections , by Region USD Million (2023-2028)
  • Table 210. Dermatology Drugs Acne , by Region USD Million (2023-2028)
  • Table 211. Dermatology Drugs Dermatitis , by Region USD Million (2023-2028)
  • Table 212. Dermatology Drugs Other , by Region USD Million (2023-2028)
  • Table 213. Dermatology Drugs: by Forms(USD Million)
  • Table 214. Dermatology Drugs Tablets , by Region USD Million (2023-2028)
  • Table 215. Dermatology Drugs External Use , by Region USD Million (2023-2028)
  • Table 216. Dermatology Drugs Injection , by Region USD Million (2023-2028)
  • Table 217. South America Dermatology Drugs, by Country USD Million (2023-2028)
  • Table 218. South America Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 219. South America Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 220. South America Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 221. Brazil Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 222. Brazil Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 223. Brazil Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 224. Argentina Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 225. Argentina Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 226. Argentina Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 227. Rest of South America Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 228. Rest of South America Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 229. Rest of South America Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 230. Asia Pacific Dermatology Drugs, by Country USD Million (2023-2028)
  • Table 231. Asia Pacific Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 232. Asia Pacific Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 233. Asia Pacific Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 234. China Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 235. China Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 236. China Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 237. Japan Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 238. Japan Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 239. Japan Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 240. India Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 241. India Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 242. India Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 243. South Korea Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 244. South Korea Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 245. South Korea Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 246. Taiwan Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 247. Taiwan Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 248. Taiwan Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 249. Australia Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 250. Australia Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 251. Australia Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 252. Rest of Asia-Pacific Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 253. Rest of Asia-Pacific Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 254. Rest of Asia-Pacific Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 255. Europe Dermatology Drugs, by Country USD Million (2023-2028)
  • Table 256. Europe Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 257. Europe Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 258. Europe Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 259. Germany Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 260. Germany Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 261. Germany Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 262. France Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 263. France Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 264. France Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 265. Italy Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 266. Italy Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 267. Italy Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 268. United Kingdom Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 269. United Kingdom Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 270. United Kingdom Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 271. Netherlands Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 272. Netherlands Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 273. Netherlands Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 274. Rest of Europe Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 275. Rest of Europe Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 276. Rest of Europe Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 277. MEA Dermatology Drugs, by Country USD Million (2023-2028)
  • Table 278. MEA Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 279. MEA Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 280. MEA Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 281. Middle East Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 282. Middle East Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 283. Middle East Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 284. Africa Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 285. Africa Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 286. Africa Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 287. North America Dermatology Drugs, by Country USD Million (2023-2028)
  • Table 288. North America Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 289. North America Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 290. North America Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 291. United States Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 292. United States Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 293. United States Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 294. Canada Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 295. Canada Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 296. Canada Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 297. Mexico Dermatology Drugs, by Type USD Million (2023-2028)
  • Table 298. Mexico Dermatology Drugs, by Application USD Million (2023-2028)
  • Table 299. Mexico Dermatology Drugs, by Forms USD Million (2023-2028)
  • Table 300. Dermatology Drugs Sales: by Type(K Units)
  • Table 301. Dermatology Drugs Sales Prescription-Based Drugs , by Region K Units (2023-2028)
  • Table 302. Dermatology Drugs Sales Over-the-Counter Drugs , by Region K Units (2023-2028)
  • Table 303. Dermatology Drugs Sales: by Application(K Units)
  • Table 304. Dermatology Drugs Sales Psoriasis , by Region K Units (2023-2028)
  • Table 305. Dermatology Drugs Sales Skin Infections , by Region K Units (2023-2028)
  • Table 306. Dermatology Drugs Sales Acne , by Region K Units (2023-2028)
  • Table 307. Dermatology Drugs Sales Dermatitis , by Region K Units (2023-2028)
  • Table 308. Dermatology Drugs Sales Other , by Region K Units (2023-2028)
  • Table 309. Dermatology Drugs Sales: by Forms(K Units)
  • Table 310. Dermatology Drugs Sales Tablets , by Region K Units (2023-2028)
  • Table 311. Dermatology Drugs Sales External Use , by Region K Units (2023-2028)
  • Table 312. Dermatology Drugs Sales Injection , by Region K Units (2023-2028)
  • Table 313. South America Dermatology Drugs Sales, by Country K Units (2023-2028)
  • Table 314. South America Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 315. South America Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 316. South America Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 317. Brazil Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 318. Brazil Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 319. Brazil Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 320. Argentina Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 321. Argentina Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 322. Argentina Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 323. Rest of South America Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 324. Rest of South America Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 325. Rest of South America Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 326. Asia Pacific Dermatology Drugs Sales, by Country K Units (2023-2028)
  • Table 327. Asia Pacific Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 328. Asia Pacific Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 329. Asia Pacific Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 330. China Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 331. China Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 332. China Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 333. Japan Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 334. Japan Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 335. Japan Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 336. India Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 337. India Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 338. India Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 339. South Korea Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 340. South Korea Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 341. South Korea Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 342. Taiwan Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 343. Taiwan Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 344. Taiwan Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 345. Australia Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 346. Australia Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 347. Australia Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 348. Rest of Asia-Pacific Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 349. Rest of Asia-Pacific Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 350. Rest of Asia-Pacific Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 351. Europe Dermatology Drugs Sales, by Country K Units (2023-2028)
  • Table 352. Europe Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 353. Europe Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 354. Europe Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 355. Germany Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 356. Germany Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 357. Germany Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 358. France Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 359. France Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 360. France Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 361. Italy Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 362. Italy Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 363. Italy Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 364. United Kingdom Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 365. United Kingdom Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 366. United Kingdom Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 367. Netherlands Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 368. Netherlands Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 369. Netherlands Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 370. Rest of Europe Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 371. Rest of Europe Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 372. Rest of Europe Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 373. MEA Dermatology Drugs Sales, by Country K Units (2023-2028)
  • Table 374. MEA Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 375. MEA Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 376. MEA Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 377. Middle East Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 378. Middle East Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 379. Middle East Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 380. Africa Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 381. Africa Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 382. Africa Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 383. North America Dermatology Drugs Sales, by Country K Units (2023-2028)
  • Table 384. North America Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 385. North America Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 386. North America Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 387. United States Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 388. United States Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 389. United States Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 390. Canada Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 391. Canada Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 392. Canada Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 393. Mexico Dermatology Drugs Sales, by Type K Units (2023-2028)
  • Table 394. Mexico Dermatology Drugs Sales, by Application K Units (2023-2028)
  • Table 395. Mexico Dermatology Drugs Sales, by Forms K Units (2023-2028)
  • Table 396. Dermatology Drugs: by Type(USD/Units)
  • Table 397. Research Programs/Design for This Report
  • Table 398. Key Data Information from Secondary Sources
  • Table 399. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dermatology Drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Dermatology Drugs: by Application USD Million (2017-2022)
  • Figure 6. Global Dermatology Drugs: by Forms USD Million (2017-2022)
  • Figure 7. South America Dermatology Drugs Share (%), by Country
  • Figure 8. Asia Pacific Dermatology Drugs Share (%), by Country
  • Figure 9. Europe Dermatology Drugs Share (%), by Country
  • Figure 10. MEA Dermatology Drugs Share (%), by Country
  • Figure 11. North America Dermatology Drugs Share (%), by Country
  • Figure 12. Global Dermatology Drugs: by Type K Units (2017-2022)
  • Figure 13. Global Dermatology Drugs: by Application K Units (2017-2022)
  • Figure 14. Global Dermatology Drugs: by Forms K Units (2017-2022)
  • Figure 15. South America Dermatology Drugs Share (%), by Country
  • Figure 16. Asia Pacific Dermatology Drugs Share (%), by Country
  • Figure 17. Europe Dermatology Drugs Share (%), by Country
  • Figure 18. MEA Dermatology Drugs Share (%), by Country
  • Figure 19. North America Dermatology Drugs Share (%), by Country
  • Figure 20. Global Dermatology Drugs: by Type USD/Units (2017-2022)
  • Figure 21. Global Dermatology Drugs share by Players 2022 (%)
  • Figure 22. Global Dermatology Drugs share by Players (Top 3) 2022(%)
  • Figure 23. Global Dermatology Drugs share by Players (Top 5) 2022(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 27. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 29. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 31. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 33. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 35. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. AstraZeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 37. Galderma S.A (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. Galderma S.A (Switzerland) Revenue: by Geography 2022
  • Figure 39. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Amgen Inc. (United States) Revenue: by Geography 2022
  • Figure 41. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. AbbVie Inc. (United States) Revenue: by Geography 2022
  • Figure 43. Merck KGaA. (Germany) Revenue, Net Income and Gross profit
  • Figure 44. Merck KGaA. (Germany) Revenue: by Geography 2022
  • Figure 45. Global Dermatology Drugs: by Type USD Million (2023-2028)
  • Figure 46. Global Dermatology Drugs: by Application USD Million (2023-2028)
  • Figure 47. Global Dermatology Drugs: by Forms USD Million (2023-2028)
  • Figure 48. South America Dermatology Drugs Share (%), by Country
  • Figure 49. Asia Pacific Dermatology Drugs Share (%), by Country
  • Figure 50. Europe Dermatology Drugs Share (%), by Country
  • Figure 51. MEA Dermatology Drugs Share (%), by Country
  • Figure 52. North America Dermatology Drugs Share (%), by Country
  • Figure 53. Global Dermatology Drugs: by Type K Units (2023-2028)
  • Figure 54. Global Dermatology Drugs: by Application K Units (2023-2028)
  • Figure 55. Global Dermatology Drugs: by Forms K Units (2023-2028)
  • Figure 56. South America Dermatology Drugs Share (%), by Country
  • Figure 57. Asia Pacific Dermatology Drugs Share (%), by Country
  • Figure 58. Europe Dermatology Drugs Share (%), by Country
  • Figure 59. MEA Dermatology Drugs Share (%), by Country
  • Figure 60. North America Dermatology Drugs Share (%), by Country
  • Figure 61. Global Dermatology Drugs: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • Johnson & Johnson (United States)
  • Pfizer Inc. (United States)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline plc (United Kingdom)
  • AstraZeneca (United Kingdom)
  • Galderma S.A (Switzerland)
  • Amgen Inc. (United States)
  • AbbVie Inc. (United States)
  • Merck KGaA. (Germany)
Select User Access Type

Key Highlights of Report


Dec 2023 234 Pages 91 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dermatology Drugs Market Quantitative research analysis
Global Dermatology Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bayer AG (Germany), Johnson & Johnson (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), GlaxoSmithKline plc (United Kingdom), AstraZeneca (United Kingdom), Galderma S.A (Switzerland), Amgen Inc. (United States), AbbVie Inc. (United States) and Merck KGaA. (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"High Demand for Quick Diagnosis " is seen as one of major influencing trends for Dermatology Drugs Market during projected period 2022-2028.
The Dermatology Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Dermatology Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Coenzyme A Comprehensive Study by Type (Lithium Salt, Sodium Salt, Free Acid, Others), Application (Biotechnology Research, Dietary Supplement, Therapeutic, Others) Players and Region - Global Market...
$ 3500
Acid Resistant Capsules Comprehensive Study by Type (Gelatin Acid Resistant Capsules, Vegan Acid Resistant Capsules, Pullulan Acid Resistant Capsules, HPMC Acid Resistant Capsules), Application (Heal...
$ 3650
Cannabidiol Cbd Comprehensive Study by Type (Marijuana-Derived Cannabidiol Products, Hemp-Derived Cannabidiol Products), Application (Personal Care & Cosmetics, Pharmaceutical (Anxiety, Fibromyalgia ...
$ 3750
Retrovirus Testing Comprehensive Study by Application (Hospital, Diagnostic Laboratory, Clinic), Sample (Body Fluid, Serum, Blood, Cell), Test Type (Infectivity Assay, Serological Test, Radio-immunoa...
$ 3800
Talazoparib Comprehensive Study by Type (0.25mg Capsules, 1mg Capsules), Application (Hospital, Drug Center, Clinic), Disease Type (Treat Prostate Cancer, Breast Cancers, Endometrial Cancer, Uterine ...
$ 3450
Histoplasmosis Treatment Comprehensive Study by Application (Hospitals Pharmacies, Private clinics, Drug stores and retail pharmacy, E-commerce), Drugs (Amphotericin B, Itraconazole, Ketoconazole, Ot...
$ 3450